Friday, 20 May 2022

 

 

LATEST NEWS DC orders improvement trust to prepare housing plan for next 15 years CM Jai Ram Thakur virtually inaugurates CT Scan Machine at RKGMC Hamirpur Governor presides over meeting of HP State Child Welfare Council High Commissioner of the Republic of Ghana visited LPU Campus Ojaswwee Sharma honoured with Entrepreneur & Achiever Award by Punjab Vidhansabha Speaker Kultar Singh Sandhwan Anti-tobacco drive: shops raided, 100 chalans issued Rayat Bahra University hosts a workshop on social cohesion Rahul Khanna lends voice to a video highlighting “Being Comfortable in one’s own skin” featuring people from different walks of life! Suresh Kashyap met Harsh Chauhan Chairperson for National Commission for Scheduled Tribes Coming back into red-ball cricket will suit Kane Williamson's game, and temperament : Gary Stead Centre to give Punjab 10 more CAPF companies, says Bhagwant Mann after meeting Amit Shah As captain, Sourav Ganguly built a team; not sure if Virat Kohli did : Virendra Sehwag UN chief says renewable energy "lifeline" to ending climate change Russia says 771 more Ukrainian soldiers surrender at Azovstal steel plant Alison Oliver opens up on her role in 'Conversation With Friends' Prime Minister Narendra Modi to share winning mantra with BJP national office-bearers on Friday Shooting in hometown Delhi, 'Zakhm' more special for Donal Bisht Will submit to majesty of law, says Navjot Singh Sidhu on one-year jail term Elton John documentary 'Goodbye Yellow Brick Road' up for hybrid release 206 kidney stones removed from man in Hyderabad IPL 2022: I'm in the happiest phase of my life, a phase of evolution for me, says Virat Kohli

 

AstraZeneca 3rd dose increases antibody response against Omicron

Omicron Variant, Delta Plus Covid variant, Delta Covid-19 variant, Coronavirus, Health, Research, Study, Researchers, COVID 19, Novel Coronavirus, Fight Against Corona, Covaxin, Covishield, Oxygen, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen Concentrator, Remdesivir, Liquid Medical Oxygen, Oximeter

Web Admin

Web Admin

5 Dariya News

London , 13 Jan 2022

A third dose of AstraZeneca's Covid vaccine, named Covishield in India, increases antibody response to the new vaccine-evading Omicron variant, according to a new trial published by the British-Swedish drugmaker on Thursday.The trial showed the third dose booster also increases the immune response to Beta, Delta, Alpha, and Gamma SARS-CoV-2 variants.The results of both were observed among individuals previously vaccinated with either AstraZeneca, Vaxzevria in the UK, or an mRNA vaccine.
"These important studies show that a third dose of Vaxzevria after two initial doses of the same vaccine, or after mRNA or inactivated vaccines, strongly boosts immunity against Covid-19," said Professor Sir Andrew J. Pollard, chief investigator and director of the Oxford Vaccine Group at the University of Oxford, in a statement.
"The Oxford-AstraZeneca vaccine is suitable as an option to enhance immunity in the population for countries considering booster programmes, adding to the protection already demonstrated with the first two doses," he added.
A recent study showed that AstraZeneca's shot increased antibodies when given as a booster after initial vaccination with its own shot or mRNA-based Pfizer's. But the study also noted that mRNA vaccines by Pfizer and Moderna gave the biggest boost to antibodies when given as a booster dose.AstraZeneca said that the new data adds to the growing body of evidence supporting Vaxzevria as a third dose booster irrespective of the primary vaccination schedules tested, adding that it is submitting the additional data to health authorities."Given the ongoing urgency of the pandemic and Vaxzevria's increased immune response to the Omicron variant, we will continue to progress regulatory submissions around the world for its use as a third dose booster," said Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca.
Meanwhile, AstraZeneca on Thursday also welcomed the US government's announcement for the purchase of an additional 500,000 doses of its antibody drug Evusheld.
The US Food and Drug Administration (FDA) had, last month, granted emergency use authorisation to Evusheld an injectable monoclonal antibody cocktail of tixagevimab co-packaged with cilgavimab - for Covid-19 among people with weakened immune systems.It is the first antibody treatment against Covid-19 that has won an EUA from the drug regulator. Evusheld is also effective against the Omicron variant.Delivery of the additional 500,000 doses is anticipated in the first quarter of 2022, the company said in a statement.This follows the previous government agreement for the purchase of 700,000 doses of Evusheld.





 

Tags: Omicron Variant , Delta Plus Covid variant , Delta Covid-19 variant , Coronavirus , Health , Research , Study , Researchers , COVID 19 , Novel Coronavirus , Fight Against Corona , Covaxin , Covishield , Oxygen , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen Concentrator , Remdesivir , Liquid Medical Oxygen , Oximeter

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD